AAIC 2025 Abstract
Results from a Human Factor Study Supporting Safe and Effective Use of the Lecanemab Subcutaneous Autoinjector
Trial in peopleInterventions
Papers by Lynn Darden Kramer
8 results
- AAIC 2025 Abstract
Subcutaneous Lecanemab: Potential Benefits and Place in Therapy
Trial in peopleInterventions - AAIC 2025 Abstract
Lecanemab Subcutaneous Formulation for Maintenance Dosing in Early Alzheimer’s Disease (AD)
Computational studyInterventions
- AAIC 2025 Abstract
Clinical and Pharmacologic Profile of a Subcutaneous Lecanemab Formulation
Trial in peopleInterventions - AAIC 2025 Abstract
Target Engagement of Lecanemab on CSF Aβ Protofibril Toxic Species in Clarity AD
Trial in peopleInterventions